Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329522 | 0.82 | HTR2C (0.55) | HTR2CSIGMAR1CCNT1CDK9EHMT2 | |
| SCHEMBL4329636 | 0.74 | HTR2C (0.60) | HTR2CSIGMAR1CCNT1CDK9EHMT2 | |
| SCHEMBL17155164 | 0.70 | HTR2C (0.55) | HTR2CSIGMAR1CCNT1CDK9HTR6 | |
| SCHEMBL28107872 | 0.70 | QDPR (0.51) | HTR2CSIGMAR1CCNT1CDK9 | |
| SCHEMBL17154231 | 0.70 | HTR2C (0.51) | HTR2CSIGMAR1CCNT1CDK9HTR6 | |
| Hydrochloric Acid SCHEMBL652812 | 0.69 | HTR2C (1.00) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| SCHEMBL27598376 | 0.69 | HTR2C (0.46) | HTR2CSIGMAR1CCNT1CDK9HTR6 | |
| SCHEMBL4049394 | 0.68 | HTR2C (0.55) | HTR2CSIGMAR1CCNT1CDK9HTR6 | |
| SCHEMBL3547373 | 0.68 | CCNT1 (0.61) | CCNT1CDK9EHMT2EHMT1 | |
| SCHEMBL27823155 | 0.68 | HTR2C (0.55) | HTR2CSIGMAR1CCNT1CDK9HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | HTR2C 106/4885SIGMAR1 247/4885CCNT1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.